Mortality in individuals with Type 2 diabetes and heart disease in a unique New Zealand population

Diabetic Medicine

Volumn 23, Issue 12, 2006, Pages 1313-1318

  Kerr, G D ^a,d   Gamble, G D ^b   Doughty, R N ^b   Simmons, D ^c   Baker, J ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Congestive cardiac failure; Maori; Mortality; Myocardial infarction; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEART DISEASE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PRIMARY MEDICAL CARE; SYSTOLIC BLOOD PRESSURE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; OCEANIC ANCESTRY GROUP;

EID: 33751209451     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01982.x     Document Type: Article

References (21)

1. Donnan PT, Boyle DIR, Broomhall J, Hunter K, McDonald TM, Newton RW et al. Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study. Diabetic Med 2002; 19: 448-455.
2. Nichols GA, Erby JR, Hillier TA, Brown JB. Congestive heart failure in Type 2 diabetes. Diabetes Care 2001; 24: 1614-1619.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355: 253-259.
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005-2016.
7. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pederson O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med 2003; 348: 383-393.
8. Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med J 2005; 81: 481-490.
9. Ministry of Health, New Zealand. Modelling Diabetes: A Summary. Public Health Intelligence Occasional Bulletin no. 11, Wellington, New Zealand: Ministry of Health, 2002.
10. Simmons D, Fleming CE, Cutfield R, Patel A, Innes J, Wellingham J. The Diabetes Care Support Service for general practitioners in Auckland. NZ Med J 1997; 110: 48-50.
11. Simmons D, Bhoopatkar H. Diabetes and hyperglycaemia among patients with myocardial infarction in a multiethnic population. Aust NZ J Med 1998; 28: 207-209.
12. Bhoopatkar H, Simmons D. Diabetes and hyperglycaemia among patients with congestive cardiac failure in a multiethnic population. NZ Med J 1996; 109: 268-270.
13. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93: 870-875.
14. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-236.
15. The SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017-1020.
16. Doughty RN, Bagg W, Gamble GD, Sharpe N, Wright SP. Impact of diabetes mellitus on all-cause mortality following first admission for heart failure in New Zealand. Eur Heart J 2001; 22: 264.
17. Bonita R, Broad JB, Beaglehole R. Ethnic differences in stroke incidence and case fatality in Auckland, New Zealand. Stroke 1997; 28: 758-761.
18. Tukuitonga CF, Stewart AW, Beaglehole R. Coronary heart disease among Pacific Island people in New Zealand. NZ Med J 1990; 103: 448-449.
19. Smith AH, Pearce NE. Determinants of differences in mortality between New Zealand Maoris and non-Maoris aged 15-64 years. NZ Med J 1984; 97: 101-108.
20. Simmons D, Schaumkel J, Cecil A, Scott J, Kenealy T. High impact of nephropathy on 5-year mortality rates among patients with Type 2 diabetes mellitus from a multi-ethnic population in New Zealand. Diabetic Med 1999; 16: 926-931.
21. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002; 359: 1430-1432.